Shares of TG Therapeutics spiked 12% on Feb. 5 after the US Food and Drug Administration (FDA) approved Ukoniq (umbralisib), its investigational compound, …
H.C.
Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with …
TG Therapeutics Inc (NASDAQ:TGTX) announced that the U.S.
TG Therapeutics Inc (NASDAQ:TGTX) announced the opening of an investigator initiated Phase 2 study at the University of Nebraska Medical Center (UNMC) to …
TG Therapeutics Inc (NASDAQ:TGTX) announced the publication of clinical data from a Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 …
TG Therapeutics Inc (NASDAQ:TGTX) announced the presentation yesterday of data from three combination studies involving the Company’s lead compounds, TGR-1202, the Company’s once-daily …
TG Therapeutics, Inc. (NASDAQ:TGTX) announced the presentation yesterday of two preclinical data sets, one oral presentation and one poster presentation, for TGR-1202, the …
TG Therapeutics Inc (NASDAQ:TGTX) announced that the independent Data Safety Monitoring Board (DSMB) providing oversight for the UNITY-CLL Phase 3 trial reviewed the …
TG Therapeutics, Inc. (NASDAQ:TGTX) announced its financial results for the third quarter ended September 30, 2016 and recent company developments.
